Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) released its earnings results on Thursday. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07, Zacks reports.
Enliven Therapeutics Price Performance
ELVN traded down $0.73 during trading on Thursday, hitting $20.29. 141,655 shares of the stock traded hands, compared to its average volume of 231,401. The firm has a market capitalization of $991.35 million, a P/E ratio of -10.68 and a beta of 1.04. The firm has a 50-day moving average of $21.73 and a 200 day moving average of $23.84. Enliven Therapeutics has a 12-month low of $10.90 and a 12-month high of $30.03.
Insider Buying and Selling at Enliven Therapeutics
In other news, CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $325,520. This represents a 7.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 21,700 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The disclosure for this sale can be found here. Insiders sold 47,784 shares of company stock valued at $1,092,375 in the last quarter. Company insiders own 29.20% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Enliven Therapeutics
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
- Five stocks we like better than Enliven Therapeutics
- Best Aerospace Stocks Investing
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Earnings Per Share Calculator: How to Calculate EPS
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is a Stock Market Index and How Do You Use Them?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.